Separation Of Nucleic Acid Patents (Class 530/821)
  • Patent number: 7807785
    Abstract: The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: October 5, 2010
    Assignee: Institute for Systems Biology
    Inventor: Biaoyang Lin
  • Patent number: 7074894
    Abstract: An isolated antigen against a Mycoplasma, prepared by a method including providing a sample of a Mycoplasma and an antibody probe, probing the Mycoplasma sample with the antibody probe to detect at least one antigen, and isolating the antigen detected. The antibody probe includes at least one antibody against the Mycoplasma that is produced by a method including (a) providing a biological sample taken a short time after an immune animal has been challenged with a Mycoplasma or Mycoplasma extract taken from the infection site or an area of a lesion or an area close to the infection site or lesion; (b) isolating cells from the biological sample; (c) culturing the cells in vitro in a suitable culture medium; and (d) harvesting antibodies produced from the cell.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: July 11, 2006
    Assignee: The University of Melbourne
    Inventors: John Walker, Rogan Lee, Stephen William Doughty
  • Patent number: 5252328
    Abstract: A composition for protecting swine against mycoplasmal pneumonia caused by M. hyopneumoniae which includes at least one protein which is an M. hyopneumoniae antigen. The M. hyopneumoniae antigen is present in an amount effective for protection of swine against mycoplasmal pneumonia caused by M. hyopneumoniae. A preferred antigen is the M. hyopneumoniae 74.5 kda antigen.
    Type: Grant
    Filed: April 7, 1989
    Date of Patent: October 12, 1993
    Assignee: Martin Marietta Energy Systems, Inc.
    Inventors: Daryl Faulds, Mimi Vishoot, Emily Brooks
  • Patent number: 5240706
    Abstract: A method for protecting an animal, in particular swine, against mycoplasma pneumonia by administering intranasally to the animal a vaccine containing one or more proteins which elicits an antibody which recognizes a Mycoplasma hyopneumoniae antigen which lacks immunosuppressive activity. A particularly preferred intranasal vaccine includes the 74.5 kDa antigen of Mycoplasma hyopneumoniae. The 74.5 kDa antigen may be of recombinant origin.
    Type: Grant
    Filed: April 7, 1989
    Date of Patent: August 31, 1993
    Assignee: ML Technology Ventures, L.P.
    Inventor: Daryl Faulds
  • Patent number: 5204257
    Abstract: A method of recovering nucleic acid-containing particles from a liquid medium by contacting the liquid medium containing the particles with a mixture of hydroxylated silica beads and a salt solution to bind the nucleic acid-containing particles, centrifuging the mixture to pellet the bound particles, and separating the pellet from the liquid.
    Type: Grant
    Filed: April 29, 1991
    Date of Patent: April 20, 1993
    Assignee: Autogen Instruments, Inc.
    Inventors: David A. DeBonville, Kelley A. Logan
  • Patent number: 5019391
    Abstract: A composition for the treatment of the skin comprises a fraction of a mechanically obtained lysate of yeast cultures of the species Saccharomyces cerevisiae. The translation system contained in the compositions of the invention are obtained by lysing cultures of Saccharomyces cerevisiae. The application of such composition, in any suitable form, such as a cream, ointment, gel or the like, to skin promotes protein biosynthesis by the skin cells so that the metabolism of the extracellular matrix of the skin is restored to the physiologically correct balance and the skin is revitalized.
    Type: Grant
    Filed: August 23, 1988
    Date of Patent: May 28, 1991
    Assignee: HEYL Chemisch-parmazeutische Fabrik GmbH & Co KG
    Inventors: Thomas Bunte, Wolfgang Parr, Eduard Heyl
  • Patent number: 4923978
    Abstract: The process for separating the proteinaceous materials from nucleic acids involves contacting a solution containing the proteinaceous materials and nucleic acids with a solid phase extraction material capable of binding proteins to form bound and unbound fractions and then isolating the unbound fraction containing the nucleic acids.
    Type: Grant
    Filed: December 28, 1987
    Date of Patent: May 8, 1990
    Assignee: E. I. Du Pont de Nemours & Company
    Inventor: Randy M. McCormick
  • Patent number: 4714613
    Abstract: A selective method of suppressing the growth of cells which express a viral antigen on the surface thereof, which comprises administering to the cells a growth suppressing amount of a monoclonal antibody against said viral antigen, especially a method of suppressing the growth of hepatocytes or hepatoma cells persistently infected with HBsAg which comprises administering to the cells a growth suppressing or lethal amount of a complement fixing monoclonal IgM or IgG.sub.2a antibody against HBsAg.
    Type: Grant
    Filed: September 30, 1982
    Date of Patent: December 22, 1987
    Assignees: The Albert Einstein College of Medicine of Yeshiva University, The General Hospital Corporation
    Inventors: Daniel Shouval, David A. Shafritz, Jack R. Wands
  • Patent number: 4701442
    Abstract: A process for preparing nucleoproteic material which comprises immersing organic material into a suitable solvent for a sufficient time to extract nucleoproteins from said material, adding a sufficient amount of an acid to form a precipitate of nucleoproteic material, and recovering said nucleoproteic material precipitate. A composition of nucleoproteic material produced according to this process. A method for alleviating symptoms of neoplastic diseases which comprises sterilizing the composition of nucleoproteic material, preparing a formulation comprising an effective amount of said sterilized composition, and administering said formulation to a patient having symptoms of a neoplastic disease.
    Type: Grant
    Filed: June 13, 1985
    Date of Patent: October 20, 1987
    Assignee: Elena Avram
    Inventor: Emanuel Revici
  • Patent number: RE33405
    Abstract: A prostate antigen distinct from prostatic acid phosphatase has been detected in normal, benign hypertrophic and malignant prostatic tissues, but not in other human tissues. The prostate antigen was purified to homogeneity from prostatic tissues by ammonium sulfate precipitation, DEAE-BioGel A anion exchange chromatography, molecular sievings on Sephadex G-100 and Sephadex G-75,This invention was supported in part by Grants No. CA-15126 and CA-15437 from the National Cancer Institute, U.S. Public Health Service.
    Type: Grant
    Filed: October 4, 1988
    Date of Patent: October 23, 1990
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Tsann M. Chu, Ming C. Wang, Lawrence Papsidero